We have just finished another Due Diligence assignment commissioned by GIMV. Our job was to assess the lead project and unique delivery technology of a European biopharmaceutical company. We have evaluated their preclinical pharmacology, pharmacokinetics and safety data, scientific rationale, competitive positioning, development plan, and Phase I results.
In the past four months we have supported an academic research team with R&D strategy advice, medical affairs, and business development activities in their efforts to create a new start-up company aimed at repositioning a currently marketed drug for a chronic human disease. We are happy to announce that with our help the team successfully secured seed funding from a biotech investor and the company has been launched.
Besides supporting Akron Molecules AG in clinical development of human medicines, we are now also providing R&D consultancy and project management activities for their clinical development program aimed at treating chronic pain in dogs.
Today we have signed a partnership agreement with Aquincum Incubator, one of the leading startup development centers in Hungary. Pro Scientia will provide Aquincum Incubator with due diligence and expert evaluation services in the coming months, with the purpose of identifying promising projects that can serve as the basis of new biopharmaceutical startup and spinoff companies.
We are excited to announce that the EU Erasmus project “European Cooperation for Improved Application of Academic Teaching in Commercial Uses of Medical Biotechnology” has delivered 4 key recommendations with our participation to improve biotechnology education and the industry-readiness of MSc graduates, including:
- European Industry Board for Graduate Biotechnology Education: ensuring maximum industry environment and culture awareness and understanding in MSc graduates
- Classification of MSc courses in Europe: enabling students and employers to select courses that deliver the desired skills and direct industry exposure
- Postgraduate alumni network : enabling MSc students to plan career development through direct industrial alumni feedback and support
- Enhancing industry placement access: to enable maximum direct industry experience for MSc students.
Full recommendations are available for download at www.ecatcub.eu
We have started to provide medical consultancy services to Akron Molecules AG, in support of their upcoming Phase II clinical trial in the field of chronic pain therapy.
We are happy to announce that our Founder has been elected into the Expert Panels on Biomarkers and Orphan/Rare Diseases by the European Society for Translational Medicine. This is an excellent opportunity to expand our network among professionals active in the Pharmaceutical R&D and Clinical translational medicine fields. The Society is going to have its annual conference in 14-16 October, 2013 in Luxembourg.
Together with our partner, Bionity R&D Investment Advisors, we are conducting fundraising activites related to establishing a preclinical CRO start-up in Hungary. The business plan is based on a truly innovative and patented technology invented by the founder and scientific director, allowing the implementation of services much needed by pharmaceutical companies, academic partners and CROs. Therefore, we are convinced that the fundraising will be successful with the participation by one of the Jeremie Venture Funds.
We have just finished another Due Diligence report of a major biopharmaceutical project. This time our client was GIMV, an independent investment company based in Belgium. I really like their tagline: GIMV – Good Company for Companies.
In the past few weeks, we have been advising BGI Health Europe to support their activities in Central and Eastern Europe in the field of Pharmacogenomics.
In collaboration with our business partner, RegInfo Ltd, we have started to assist Sanofi Pharmaceuticals with regulatory information management for product series of Sanofi in the field of CMC.
Our Erasmus industry survey is now closed.
A big thanks to all of you who responded to our questions! Together with our consortium partners we are now starting the analysis of the industrial, academic and student surveys. The results will be used to provide recommendations on improving Medical Biotechnology MSc training programmes to better serve the needs of the industry. We hope that in the project we will be able to develop a cooperation between academy and the industrial partners for a more successful commercial use of medical biotechnology skills.
We are currently conducting discussions with a large genomics company about a joint project in pharmacogenomics. Details will be published soon.
Between July 2012 and February 2013, we have been supporting the out-licensing process by Sanofi Pharmaceuticals of three truly innovative R&D projects in the field of chronic obstructive pulmonary disease (COPD). We have conducted extensive discussions with investors pertinent to clinical development, regulatory affairs, competitive positioning, and the business plan of the proposed spin-off company.
Today we have launched our brand new web site. Besides the new and updated content the design is now responsive, meaning that the page layout will change according to your browser dimensions to provide an optimal viewing experience — easy reading and navigation with a minimum of resizing, panning, and scrolling — across a wide range of devices (from desktop computer monitors to tablets and mobile phones).
You can try it right now: just resize your browser window, and the layout will change instantly.
We are proud to announce that our Founder has been elected into the Advisory Board of TranScientae, LLC (USA).
TranScientae, LLC is a translational research consulting firm focused on helping biomedical science-based organizations solve the complex challenges associated with modern drug discovery and development.
Our LinkedIn page has been created to facilitate networking with our current and prospective clients.
Have your say – share your experiences – build the future!
We are part of an Erasmus project with the mission to build scientific MSc courses in Europe that deliver strong industry-academic partnerships and industry-ready graduates – serving Europe’s innovative life sciences sector. You play a key role in helping achieve this. If you are an industry player in company large or small, we need your experiences and needs with regard to creating industry-ready graduates.
We invite you to complete a very short online survey, where we establish your experiences and interaction with MSc courses and graduates. Even if you have no contact with courses or graduates in your company, we want to know why, as this itself is a bottleneck to creating industry-academic partnerships.
Thank you for your input. Together, we can build the MSc graduate for European success.
Pro Scientia gave a successful presentation at a special symposium of the HealthBio Partnering Summit in Helsinki, titled: “An MSc fit for industry - the big pharma perspective”.
The conclusions of the discussions following the presentations of the symposium will be incorporated into the upcoming Biotechnology Industry Survey.
Pro Scientia Ltd. currently participates in an EU project within the Erasmus Lifelong Learning Programme titled „European Cooperation for Improved Application of Academic Teaching in Commercial Uses of Medical Biotechnology”. Our aim is to evaluate the view of the European pharma and biotech players on Medical Biotechnology MSc training programmes, with the goal to better understand the skill requirements and knowledge gaps of fresh graduates from industry perspective.
Other consortium partners in this project are: